- Name: Qiu Miao-zhen
- Title: Attending doctor
- Email: qiumzh@sysucc.org.cn
- Phone:
Dr. Miao-Zhen Qiu is currently a professor in the Department of Medical Oncology at Sun Yat-Sen University Cancer Center, Guangzhou, China. She has extensive experience and expertise in the field of treatment and translation research in gastrointestinal cancers. Dr Qiu has initiated or participated in many investigator initiated and NMPA approved clinical trials. She presides over a number of research programs including programs from the National Natural Science Foundation of China. Dr. Wang has published over 70 peer-reviewed articles as first author or corresponding author in renowned journals such as JAMA Oncology, Cell Reports. She and has been invited to present her research results at ASCO, CSCO, GAP, Chinese Congress of Oncology and other international conferences. She was awarded many prizes including the Second Prize of National Science and Technology Progress Award, First Prize of Chinese Medical Science and Technology Award, the First Prize of Guangdong Province Science and Technology Progress Award, as well as the Outstanding Young Talents of Sun Yat-sen University Cancer Center.
Education:
/2001-6/2006 Bachelor degree, Medical Science, Sun Yat-sen University6/2006-7/2008 Master degree, Medical Oncology, Sun Yat-sen University
9/2012-06/2015 PhD, Oncology, Sun Yat-sen University
Professional Experience (in chronological order, earliest first)8/2008-12/2011 Resident doctor, Department of medical oncology, Sun Yat-senUniversity
12/2011-12/2017 Attending doctor, Department of medical oncology, Sun Yat-sen University
2017/12-12/2022 Associated professor Department of medical oncology, Sun Yat-sen University
12/2022-present Professor Department of medical oncology, Sun Yat-sen University
(1)Qiu MZ#, Chen Q#, Zheng DY#, Zhao Q#, Wu QN#, Zhou ZW, Yang LQ, Luo QY, Sun YT, Lai MY, Yuan SS, Wang FH, Luo HY, Wang F, Li YH, Zhang HZ, Xu RH*. Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins. Cell Rep. 2023 Jun 6;42(6):112576.
(2)Qiu MZ#, Zhang Y#, Guo Y, Guo W, Nian W, Liao W, Xu Z, Zhang W, Zhao HY, Wei X, Xue L, Tang W, Wu Y, Ren G, Wang L, Xi J, Jin Y, Li H, Hu C, Xu RH*. Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1042-1046.
(3)Lin JF#, Hu PS#, Wang YY#, Tan YT#, Yu K, Liao K, Wu QN, Li T, Meng Q, Lin JZ, Liu ZX, Pu HY, Ju HQ*, Xu RH*, Qiu MZ*. Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis. Signal Transduct Target Ther. 2022 Feb 28;7(1):54.
(4)Zhang Y#, Qiu MZ#, Wang JF, Zhang YQ, Shen A, Yuan XL, Zhang T, Wei XL, Zhao HY, Wang DS, Zhao Q, Xiong GZ, Ji YP, Liang XJ, Xia G, Xu RH*. Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. Cell Rep Med. 2022 Nov 15;3(11):100814.
(5)Zhang Z#, Wang ZX#, Chen YX#, Wu HX#, Yin L, Zhao Q, Luo HY, Zeng ZL, Qiu MZ*, Xu RH*. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. Genome Med. 2022 Apr 29;14(1):45.
(6)Liu ZX#, Zhang XL#, Zhao Q#, Chen Y, Sheng H, He CY, Sun YT, Lai MY, Wu MQ, Zuo ZX, Wang W, Zhou ZW, Wang FH, Li YH, Xu RH*, Qiu MZ*. Whole-Exome Sequencing Among Chinese Patients With Hereditary Diffuse Gastric Cancer. JAMA Netw Open. 2022 Dec 1;5(12):e2245836.
(7)Meng Q#, Lu YX#, Ruan DY#, Yu K, Chen YX, Xiao M, Wang Y, Liu ZX, Xu RH, Ju HQ*, Qiu MZ*. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer. Mol Ther Nucleic Acids. 2021 Apr 3;24:695-710.
(8)Luo F#, Lu FT#, Qiu MZ#, Zhou T, Ma WJ, Luo M, Zeng KM, Luo QY, Pan WT, Zhang L, Xia ZF, Zhang ZH, Cao JX, Zhao HY*, Zhang L*, Yang DJ*. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway. Cell Death Dis. 2021 Aug 5;12(8):772.
(9)He CY#, Qiu MZ#, Yang XH#, Zhou DL, Ma JJ, Long YK, Ye ZL, Xu BH, Zhao Q, Jin Y, Lu SX, Wang ZQ, Guan WL, Zhao BW, Zhou ZW, Shao JY*, Xu RH*. Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis. Clin Transl Med. 2020 Jan;10(1):353-362.
(10)Qiu MZ#, He CY#, Lu SX#, Guan WL, Wang F, Wang XJ, Jin Y, Wang FH, Li YH, Shao JY, Zhou ZW, Yun JP, Xu RH*. Prospective observation: Clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients. Int J Cancer. 2020 Jan 1;146(1):272-280.
(11)Luo QY#, Di T#, Chen ZG#, Peng JH, Sun J, Xia ZF, Pan WT, Luo F, Lu FT, Sun YT, Yang LQ, Zhang L*, Qiu MZ*, Yang DJ*. A novel prognostic model predicts overall survival in colon cancer based on RNA splicing regulation gene expression. Cancer Sci. 2022 Oct;113(10):3330-3346.
(12)Luo QY#, Zhou SN#, Pan WT#, Sun J, Yang LQ, Zhang L*, Qiu MZ*, Yang DJ*. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition. Biochem Pharmacol. 2021 Jan;183:114318.
(13)Sun YT#, Guan WL#, Zhao Q, Wang DS, Lu SX, He CY, Chen SZ, Wang FH, Li YH, Zhou ZW, Xu RH, Qiu MZ*. PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. Am J Cancer Res. 2021 Oct 15;11(10):5006-5015.
(14)Qiu MZ#*, He CY#, Yang XH#, Yang LQ, Lin JZ, Zhou DL, Long YK, Guan WL, Jin Y, Li YH, Wang FH, Yang DJ*, Xu RH*. Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma. Oncologist. 2021 Jul;26(7):e1161-e1170.
(15)Li ZC#, Sun YT#, Lai MY#, Zhou YX*, Qiu MZ*. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis. Int Immunopharmacol. 2022 Aug;109:108790.
Updated by International Office, Sun Yat-sen University Cancer Center